ArticleJournal of virology1997
A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro.
Article in Journal of virology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 101 citations in OpenAlex.
- Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine.Vaccine · 2007Trial
- CircRNA based multivalent neuraminidase vaccine induces broad protection against influenza viruses in mice.NPJ vaccines · 2024Article
- COBRA Hemagglutinin and cGAMP Loaded Ace-DEX Microparticles Provide a Broadly Active and Shelf-Stable Influenza Vaccine Platform.Advanced therapeutics · 2024Article
- A mosaic influenza virus-like particles vaccine provides broad humoral and cellular immune responses against influenza A viruses.NPJ vaccines · 2023Article
- Self-Assembled TLR7/8 Agonist-Mannose Conjugate as An Effective Vaccine Adjuvant for SARS-CoV-2 RBD Trimer.Polymers · 2022Article
- Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats.Advanced nanobiomed research · 2022Article
- Polycationic HA/CpG Nanoparticles Induce Cross-Protective Influenza Immunity in Mice.ACS applied materials & interfaces · 2022Article
- Original Antigenic Sin: How Original? How Sinful?Cold Spring Harbor perspectives in medicine · 2021Review
- Guidance for Healthcare Providers Managing COVID-19 in Rural and Underserved Areas.Journal of racial and ethnic health disparities · 2020Article
- Biological sex affects vaccine efficacy and protection against influenza in mice.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Antibody-Dependent Cell-Mediated Cytotoxicity to Hemagglutinin of Influenza A Viruses After Influenza Vaccination in Humans.Open forum infectious diseases · 2016Article
- Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine.Vaccine · 2016Observational
- Convalescent plasma: new evidence for an old therapeutic tool?Blood transfusion = Trasfusione del sangue · 2016Review
- H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix(®) vaccination.Immunology · 2015Article
- Focused antibody response to influenza linked to antigenic drift.The Journal of clinical investigation · 2015Article
- Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.Vaccine · 2015Article
- Article
- Effect of receptor binding specificity on the immunogenicity and protective efficacy of influenza virus A H1 vaccines.Virology · 2014Article
- Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine.PloS one · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
We have previously shown that a pulmonary influenza virus infection in SCID mice can be cured by treatment with monoclonal antibodies (MAbs) specific for the viral transmembrane protein hemagglutinin (HA) but not for matrix 2. Since both types of MAbs react with infected cells but only the former neutralizes the virus, it appeared that passive MAbs cured by neutralization of progeny virus rather than reaction with infected host cells. To prove this, we selected a set of four HA-specific MAbs, all of the immunoglobulin G2a isotype, which reacted well with native HA expressed on infected cells yet differed greatly (>10,000-fold) in virus neutralization (VN) activity in vitro, apparently because of differences in antibody avidity and accessibility of the respective determinants on the HA of mature virions. Since the VN activities of these MAbs in vitro were differentially enhanced by serum components, we determined their prophylactic activities in vivo and used them as measures of their actual VN activities in vivo. The comparison of therapeutic and prophylactic activities indicated that these MAbs cured the infection to a greater extent by VN activity (which was greatly enhanced in vivo) and to a lesser extent by reaction with infected host cells. Neither complement- nor NK cell-dependent mechanisms were involved in the MAb-mediated virus clearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.